Finance

Lists
524804:BOM
Aurobindo Pharma Ltd
1 658,65 ₹
-0,98%
(-16,35) 1D
16 қаз., 15:30:00 GMT+5:30  ·   INR
All symbols
SymbolPriceChange% Change
Generating top insights for 524804...
Open
1 683,55 ₹
High
1 683,55 ₹
Low
1 654,75 ₹
Mkt. cap
959,10 млрд
Avg. vol.
29,66 мың
Volume
11,19 мың
P/E ratio
25,92
52-wk high
1 739,95 ₹
52-wk low
1 080,10 ₹
EPS
64,00 ₹
Shares outstanding
585,90 млн
No. of employees
29 мың
Open
1 683,55 ₹
High
1 683,55 ₹
Low
1 654,75 ₹
Mkt. cap
959,10 млрд
Avg. vol.
29,66 мың
Volume
11,19 мың
P/E ratio
25,92
52-wk high
1 739,95 ₹
52-wk low
1 080,10 ₹
EPS
64,00 ₹
Shares outstanding
585,90 млн
No. of employees
29 мың
News stories
From web sources and news partners
Profile
Aurobindo Pharma Limited is an Indian multinational pharmaceutical manufacturing company based in HITEC City, Hyderabad, with U.S. headquarters in East Windsor, Mercer County, New Jersey. The company manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company's area of activity includes six major therapeutic and product areas: antibiotics, anti-retrovirals, cardiovascular products, central nervous system products, gastroenterologicals, and anti-allergics. The company markets these products in over 125 countries. Its marketing partners include Pfizer and AstraZeneca. Wikipedia
About Aurobindo Pharma Ltd
CEO-
Employees29,2 мың
Founded1986
HeadquartersХайдарабад, Андхра-Прадеш, Үндістан
SectorPharmaceutical industry
Previous reportsAll values in INR
Loading Previous Earnings...
Revenue
Net income
All values in INR
2025 ж. қыр.
2025 ж. жел.
2026 ж. нау.
2026 ж. мау.
Revenue
82,86 млрд
86,46 млрд
88,53 млрд
91,50 млрд
Cost of goods sold
33,39 млрд
34,81 млрд
39,28 млрд
36,27 млрд
Cost of revenue
33,39 млрд
34,81 млрд
39,28 млрд
36,27 млрд
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
12,77 млрд
13,10 млрд
14,31 млрд
14,80 млрд
Operating expense
36,98 млрд
38,56 млрд
35,29 млрд
41,29 млрд
Total operating expenses
70,37 млрд
73,37 млрд
74,57 млрд
77,56 млрд
Operating income
12,49 млрд
13,09 млрд
13,96 млрд
13,94 млрд
Other non operating income
1,16 млрд
1,54 млрд
-2,51 млрд
2,12 млрд
EBT including unusual items
12,76 млрд
13,39 млрд
12,91 млрд
15,15 млрд
EBT excluding unusual items
12,76 млрд
14,04 млрд
13,59 млрд
15,55 млрд
Income tax expense
4,28 млрд
4,29 млрд
3,70 млрд
4,83 млрд
Effective tax rate
33,53%
32,03%
28,65%
31,88%
Other operating expenses
19,91 млрд
20,81 млрд
16,37 млрд
21,62 млрд
Net income
8,48 млрд
9,10 млрд
9,21 млрд
10,33 млрд
Net profit margin
10,24%
10,53%
10,41%
11,28%
Earnings per share
14,61
16,43
15,86
17,46
Interest and investment income
-
-
3,31 млрд
-
Interest expense
-952,40 млн
-927,70 млн
-665,50 млн
-1,02 млрд
Net interest expenses
-952,40 млн
-927,70 млн
2,65 млрд
-1,02 млрд
Depreciation and amortization charges
4,29 млрд
4,65 млрд
4,61 млрд
4,87 млрд
EBITDA
16,66 млрд
16,71 млрд
18,03 млрд
18,01 млрд
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
Google қолданбалары